Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors

Currently, renal cell carcinoma is characterized by encouraging benefits from immunotherapy that have led to significant results in treatment outcome. The approval of nivolumab primarily as second-line monotherapy and, more recently, the approval of new combination therapies as first-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Schepisi, Giuseppe, Conteduca, Vincenza, Casadei, Chiara, Gurioli, Giorgia, Rossi, Lorena, Gallà, Valentina, Cursano, Maria Concetta, Brighi, Nicole, Lolli, Cristian, Menna, Cecilia, Farolfi, Alberto, Burgio, Salvatore Luca, Altavilla, Amelia, Martinelli, Giovanni, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538692/
https://www.ncbi.nlm.nih.gov/pubmed/33072597
http://dx.doi.org/10.3389/fonc.2020.565857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538692/
https://www.ncbi.nlm.nih.gov/pubmed/33072597
http://dx.doi.org/10.3389/fonc.2020.565857

Ejemplares similares